Accelerated development of mRNA vaccine against avian influenza (H5N1)
Sinergium Biotech has launched a project to accelerate the development of mRNA vaccines against avian flu
Argentine company Sinergium Biotech recently launched a new project to accelerate the development of mRNA vaccines against human avian influenza (H5N1). This initiative, supported by the World Health Organization (WHO) and the Medicines Patent Pool (MPP), aims to strengthen the capacity of low- and middle-income countries to produce vaccines themselves.
A new weapon against avian influenza
H5N1 avian influenza represents a highly pathogenic virus capable of transmitting from birds to humans and causing severe, often fatal, illness. Its ability to mutate rapidly makes it difficult to develop traditional vaccines. In contrast, mRNA technology offers a faster and more flexible solution, allowing the vaccine to be rapidly adapted to new viral variants.
The innovative mRNA technology
Messenger RNA technology, mRNA, made famous by anti-COVID vaccines, once again proves to be a powerful tool in the fight against infectious diseases. Indeed, thanks to this technology, new vaccines can be rapidly developed and adapted to evolving viruses such as avian flu.
Twofold goal of the project
The goal of the development project is twofold: first, to create an effective vaccine against H5N1, a highly pathogenic virus that poses a serious threat to public health. Indeed, H5N1 avian influenza poses a constant threat to public health. Its ability to mutate rapidly and transmit from animals to humans makes the development of effective and affordable vaccines essential.
On the other hand, strengthen the production capacity of low- and middle-income countries, making them more autonomous in responding to future pandemics. “This initiative is a critical step toward a future where everyone, everywhere in the world, has access to the vaccines they need,” said WHO Director-General Tedros Adhanom Ghebreyesus.
A winning collaboration
Latin America, already at the forefront of mRNA vaccine research thanks to Sinergium Biotech, is taking this collaboration with WHO and the MPP a step further. By providing its knowledge and resources, the project enables Sinergium Biotech and other partners to accelerate vaccine development and disseminate the technology globally. This project demonstrates the importance of investing in research and development at the local level to ensure greater equity in access to health technologies.